A Gleiss Lutz team has advised J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC in their role as financial advisors to Thermo Fisher on certain German law issues in connection with the financing of a proposed acquisition of the Dutch life science tools and services company QIAGEN.
Headquartered in Venlo in the Netherlands, QIAGEN N.V. is a leading supplier of sample and assay technologies for molecular diagnostics, academic research, the pharmaceuticals industry, and applied testing procedures. Under the umbrella of the holding company, QIAGEN has more than 35 subsidiaries across over 25 countries. QIAGEN shares are traded on the New York Stock Exchange and in the Frankfurt Stock Exchange Prime Standard segment, and are also listed in the TecDAX and the MDAX.
The following Gleiss Lutz team advised the two banks on the financing: Dr. Eva Reudelhuber (partner, finance, Frankfurt, lead), Martin Hitzer (partner, corporate, Düsseldorf), Yana Koch (finance, Frankfurt), Dr. Simon Frye, Dr. Joscha Meyer (both corporate, Düsseldorf).
The US and the Netherlands law aspects were handled by Simpson Thacher and Stibbe, respectively.
Forward
